MAPT and Alzheimer disease: Our models combined imaging and fluid AD biomarkers – future studies using consistent modalities (e.g., all imaging‐based or fluid‐based) as well as more direct tau measures (e.g., tau‐PET, biofluid MTBR‐243) could refine and contextualize our findings.3, 65, 66